Baxter International Inc. (BAX) fair value analysis
S&P 500 · Updated 2026-10-19
BAX price how computed
Forward Fair Value verdict
UndervaluedBAX is trading at a 10–25% discount to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $24.35
- Sector
- Healthcare
- 12-month range
- $15.80–$28.35
- Market cap
- $12.6B
- From 52-week high
- -14.1%
- Shares outstanding
- 517M
- Rank in Healthcare by discount to fair value
- #40 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
Baxter International Inc. is a healthcare company that develops, manufactures, and distributes medical products and therapies across multiple segments including renal care, medication delivery, surgical care, and plasma-derived therapies. The company operates globally with a significant presence in North America, Europe, and other international markets.
BAX currently ranks #40 of 108 Healthcare stocks by discount to fair value. It has screened as Undervalued for 11 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $12.6B
- P/E (trailing)
- 12x
- Revenue (TTM)
- $11.5B
- Net margin
- -9.3%
- EPS (TTM)
- $2.05
- Gross margin
- 34.9%
- Debt / equity
- 1.56
- Revenue growth (3-yr avg)
- 4.6%
- Shares outstanding
- 517M
Derived indicators how computed
- Quality grade
- D
- Margin trend
- Contracting
- 52-week position
- The upper-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 68 · neutral
- 50-day average
- $25.01
- 200-day average
- $21.11
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Dividends how computed
- Paid, last 12 months
- $0.04 per share (4 payments)
- Yield on last price
- 0.16%
- Consecutive years of increases
- 0 (no streak on complete calendar years)
- Last ex-dividend date
- 2026-08-28
- Last payment date
- 2026-10-01
Earnings how computed
- Next earnings report
- 2026-10-29 (pre-market)
- Last 8 quarters vs consensus
- 5 beat, 3 missed
- Quarter by quarter
- 2026-06 ▲ beat (+55.6%)
2026-03 ▲ beat (+16.1%)
2025-12 ▼ miss (-18.5%)
2025-09 ▲ beat (+15.0%)
2025-06 ▼ miss (-3.3%)
2025-03 ▲ beat (+14.6%)
2024-12 ▲ beat (+11.5%)
2024-09 ▼ miss (-37.2%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 2 buy · 11 hold · 0 sell (13 analysts)
- Consensus lean
- Hold-leaning
- Consensus price target
- $27.9
- Target vs last price
- +14.6%
What our data shows for BAX
- Our model validated 17 trailing price-to-earnings windows for BAX, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $15.80–$28.35.
- The 14-day relative strength index sits at a neutral 68.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for BAX
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent BAX news
TickrTrends' derived news-sentiment signal for BAX is currently leaning positive, computed from recent coverage.
- FDA Issues Warning Letter to Baxter International (BAX) Over Manufacturing Violations (gurufocus.com, 2026-10-20)
TickrTrends take: The FDA warning letter regarding manufacturing violations at Baxter International raises questions about potential remediation costs and operational disruptions that could impact near-term earnings and cash flow. TickrTrends currently assesses BAX as undervalued within the Healthcare sector, but investors monitoring the valuation should track whether regulatory compliance expenses or production delays materially alter the company's financial performance going forward. The severity of the violations and timeline for resolution will be key factors in determining whether the current valuation thesis remains supportable or requires reassessment. - Baxter International Inc (BAX) Stock Up 3.1% and Still Undervalued -- GF Score: 70/100 (gurufocus.com, 2026-10-05)
TickrTrends take: Baxter International's recent 3% stock price increase has not closed the valuation gap that TickrTrends currently identifies in the Healthcare sector. The GF Score of 70 suggests moderate fundamental quality, which may support the undervalued assessment when combined with the company's current pricing. Investors focused on valuation metrics should monitor whether further price appreciation narrows the discount or if fundamental developments justify the current undervalued designation. - A Look at Baxter International Inc (BAX) After 3.3% Gain -- GF Value $31.69 vs Price $23.68 (gurufocus.com, 2026-09-22)
TickrTrends take: Baxter International trades at a notable discount to its GF Value estimate according to this recent market movement. The stock's 3 percent gain reflects broader market activity, though the valuation gap suggests the market may be pricing in concerns that differ from fundamental value models. Investors focused on valuation metrics should monitor whether this Healthcare sector company can narrow the spread between its current price and estimated fair value through operational performance or market reassessment.
More BAX news
- Is Baxter Stock Underperforming the Nasdaq? (finance.yahoo.com, 2026-09-21)
What people are saying
Follow the BAX conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for BAX show movement toward neutral positioning this week. The quality grade improved from F to D, while the Relative Strength Index zone shifted from oversold to neutral conditions. BAX maintains an undervalued valuation verdict within the Healthcare sector.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends' derived indicators for BAX show modest improvement this week, with the sector discount rank rising to #47 from #52, indicating the stock is trading at a relatively better valuation compared to other Healthcare sector companies. BAX maintains an Undervalued verdict based on current analysis.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is BAX stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), BAX is trading at a 10–25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.
What is BAX's TickrTrends verdict?
BAX's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.
How does BAX compare to other Healthcare stocks?
BAX ranks #40 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is BAX overbought or oversold?
BAX's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does BAX pay a dividend?
Yes. BAX paid $0.04 per share over the last twelve months (4 payments), a 0.16% yield on TickrTrends' last price. The last ex-dividend date was 2026-08-28.
When does BAX report earnings next?
BAX's next earnings report is scheduled for 2026-10-29 (pre-market), per the published earnings calendar.
Does BAX usually beat earnings estimates?
Over its last 8 reported quarters BAX beat the consensus estimate 5 times and missed 3 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about BAX?
Of 13 analysts covering BAX, 2 rate it a buy, 11 a hold and 0 a sell - hold-leaning, with a consensus price target of $27.9 (+14.6% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
BAX vs AQST · BAX vs BDX · BAX vs BTSG · BAX vs ENSG · BAX vs INVA